Clinical Impact of SGLT2 Inhibitor After DC Cardioversion in Persistent AF With HFpEF

Conditions

• Atrial Fibrillation
• DC Cardioversion
• SGLT2 Inhibitor

Eligibility Criteria

Sex

ALL

Age

19 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• SGLT2 inhibitors (Dapagliflozin and Empagliflozin) — DRUG
  Patients receive an SGLT2 inhibitor (empagliflozin or dapagliflozin) after successful DC cardioversion, in addition to guideline-directed anticoagulation and antiarrhythmic drugs for 1 month.

Study Details

SGLT2 inhibitors improve outcomes in heart failure across the ejection fraction spectrum, but their effect on maintenance of sinus rhythm after rhythm-control therapy is largely unknown. This prospective, single-center, open-label randomized controlled trial evaluates whether an SGLT2 inhibitor started after successful electrical cardioversion reduces recurrence of atrial tachyarrhythmia at 1 month in patients with persistent atrial fibrillation and heart failure with preserved ejection fraction. 200 patients will be randomized 1:1 to receive an SGLT2 inhibitor or no SGLT2 inhibitor.

Key Dates

First listed

Aug 20, 2026

Start date

Feb 1, 2024

Status verified

Aug 2026

Primary completion

Aug 1, 2027

Completion

Sep 1, 2027

Study Design

Enrollment

200 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: SGLT2 inihibitor
  Patients receive an SGLT2 inhibitor (empagliflozin or dapagliflozin) after successful DC cardioversion, in addition to guideline-directed anticoagulation and antiarrhythmic drugs for 1 month.
• No Intervention: Control
  Patients receive guideline-directed anticoagulation and antiarrhythmic drugs after DC cardioversion, without an SGLT2 inhibitor.

Primary Outcome Measure

Recurrence of atrial tachyarrhythmia [ Time Frame: 1 month after randomization (±1 week) ]

Central Contacts

• Juwon Kim
  +82-2-3410-2578
  [email protected]

Find similar trials

Related Studies

• Identification of Genomic Predictors of Adverse Events After Cardiac Surgery
  Recruiting · Brigham and Women's Hospital · Dallas, Texas
• Minocycline Plus Amiodarone Versus Amiodarone Alone for the Prevention of Atrial Fibrillation After Cardiac Surgery
  PHASE2 · Not Yet Recruiting · Baystate Medical Center · Melrose, Massachusetts
• Pharmacogenetic Study of Antiarrhythmic Drugs for Atrial Fibrillation
  PHASE4 · Recruiting · University of Illinois at Chicago · Chicago, Illinois
• Left Atrial Appendage Occlusion Registry (LAAO Registry)
  Recruiting · American College of Cardiology · Washington D.C., District of Columbia